Skip to Content

ASCO GI 2025: Danish Study Highlights Efficacy and Safety of Single-Cycle Neoadjuvant Pembrolizumab for Localized dMMR Colon Cancer

Findings from the RESET-C study suggest that a single cycle of neoadjuvant pembrolizumab offers high efficacy and manageable safety for patients with localized dMMR colon cancer, as presented at the ASCO Gastrointestinal Cancers Symposium.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top